Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06226610 · ClinicalTrials.gov registry record · Phase 2
Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic
A Phase 2 study of Pruritis, sponsored by Akron Children's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT06226610: Recruiting Phase 2 study of Pruritis, sponsored by Akron Children's Hospital.
NCT06226610 is a Phase 2 study of Pruritis that is actively recruiting participants, run by Akron Children's Hospital. The registered enrollment target is 46 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06226610, a Phase 2 study of Pruritis, is actively recruiting participants, sponsored by Akron Children's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to test the efficacy of Dupixent in improving post-burn itching symptoms versus the current standard of care.
Primary Outcome
Participants' Itch Severity Scale (ISS) scores will decrease more than 2.0 points after 12 weeks following initiating use of Dupixent
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Dupilumab
Study Locations (1)
Ohio
- Akron Children's Hospital - Akron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2024-11-21 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What NCT06226610 shows while recruiting
NCT06226610 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Pruritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06226610 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06226610 about?
NCT06226610 is a clinical study titled "Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic". The goal of this study is to test the efficacy of Dupixent in improving post-burn itching symptoms versus the current standard of care.
What is the current status of trial NCT06226610?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2024-11-21. Estimated completion is 2026-12-31.
What conditions does trial NCT06226610 study?
This clinical trial studies the following conditions: Pruritis.
What interventions are being tested in trial NCT06226610?
The interventions under investigation include: Placebo (OTHER), Dupilumab (DRUG).
Who is sponsoring clinical trial NCT06226610?
This trial is sponsored by Akron Children's Hospital, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06226610 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pruritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06226610's enrollment target sits among peer trials
46 1286th of 2000 higher than 706 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI